Abstract
Rationale
Augmentation therapy with serotonin-1A receptor (5-HT1A) partial agonists has been suggested to ameliorate psychotic symptoms in patients with schizophrenia.
Objective and methods
The objective of the present study was to examine the effect of repeated administration of tandospirone (0.05 and 5 mg/kg) on locomotor activity in a novel environment and on sensorimotor gating in rats treated with the N-methyl-d-aspartate receptor antagonist MK-801, which has been used in animal models of schizophrenia. Furthermore, we sought to determine whether the effect of tandospirone on these behavioural measures is blocked by WAY 100635 (0.3 mg/kg), a 5-HT1A receptor antagonist, and whether there is an interaction between haloperidol (0.1 mg/kg; a dopamine-D2 receptor antagonist) and tandospirone.
Results
Tandospirone at 5 mg/kg, but not 0.05 mg/kg, decreased locomotor activity in saline or MK-801-treated rats, which were not affected by co-treatment with WAY 100635. Haloperidol decreased locomotion both in saline and MK-801-treated animals, and this effect was not evident in the latter group receiving the higher dose of tandospirone. Tandospirone (5 mg/kg)-induced disruption of sensorimotor gating in saline or MK-801-treated animals was reversed by WAY-100635, but not by haloperidol.
Conclusions
These findings suggest that behavioural changes induced by tandospirone are not fully blocked by 5-HT1A antagonists and that tandospirone (5 mg/kg) potentiates the effect of MK-801. Overall, these findings point to an interaction between NMDA and 5-HT1A receptors. Part of the effect of tandospirone on locomotor activity may be mediated by the actions of its active metabolites on other neurotransmitter systems.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahlenius S, Hillegaart V, Salmi P, Wijkstrom A (1993) Effects of 5-HT1A receptor agonists on patterns of rat motor activity in relation to effects on forebrain monoamine synthesis. Pharmacol Toxicol 72:398–406
Amitai N, Semenova S, Markou A (2007) Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl) 193:521–537
Bubenikova V, Votava M, Horacek J, Palenicek T, Dockery C (2005) The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 80:591–596
Bubenikova-Valesova V, Horacek J, Vrajova M, Hoschl C (2008a) Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 32:1014–1023
Bubenikova-Valesova V, Stuchlik A, Svoboda J, Bures J, Vales K (2008b) Risperidone and ritanserin but not haloperidol block effect of dizocilpine on the active allothetic place avoidance task. Proc Natl Acad Sci USA 105:1061–1066
Bubenikova-Valesova V, Vales K, Stuchlik A, Horacek J (2007a) The Role of serotonin-1A receptors in learning and memory-relevance for schizophrenia. Psychiatrie 11(suppl 3):8–11
Bubenikova-Valesova V, Votava M, Palenicek T, Horacek J (2007b) The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801. Neuropharmacology 52:1071–1078
Caccia S, Garattini S, Mancinelli A, Muglia M (1982) Identification and quantitation of 1-(2-pyrimidinyl)piperazine, an active metabolite of the anxiolytic agent buspirone, in rat plasma and brain. J Chromatogr 252:310–314
Fornal CA, Metzler CW, Gallegos RA, Veasey SC, McCreary AC, Jacobs BL (1996) WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther 278:752–762
Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377
Gogos A, van den Buuse BM, Rossell S (2009) Gender differences in prepulse inhibition (PPI) in bipolar disorder: men have reduced PPI, women have increased PPI. Int J Neuropsychopharmacol 12:1249–1259
Gu Z, Jiang Q, Yan Z (2007) RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol 71:1030–1039
Haller J, Leveleki C, Halasz J, Baranyi J, Makara GB (2001) The effect of glucocorticoids on the anxiolytic efficacy of buspirone. Psychopharmacology (Berl) 157:388–394
Hamik A, Oksenberg D, Fischette C, Peroutka SJ (1990) 1422724329/0800Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites. Biol Psychiatry 28:99–109
Hensler JG (2003) Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 72:1665–1682
Hjorth S, Sharp T (1991) Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci 48:1779–1786
Koch M (1999) The neurobiology of startle. Prog Neurobiol 59:107–128
Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH (2007) NMDA receptors and schizophrenia. Curr Opin Pharmacol 7:48–55
McMillen BA, Matthews RT, Sanghera MK, Shepard PD, German DC (1983) Dopamine receptor antagonism by the novel antianxiety drug, buspirone. J Neurosci 3:733–738
McMillen BA, McDonald CC (1983) Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat. Neuropharmacology 22:273–278
Mignon L, Wolf WA (2002) Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat. Psychopharmacology (Berl) 163:85–94
Miller LG, Thompson ML, Byrnes JJ, Greenblatt DJ, Shemer A (1992) Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine. J Clin Psychopharmacol 12:341–345
Newman-Tancredi A, Nicolas JP, Audinot V, Gavaudan S, Verriele L, Touzard M, Chaput C, Richard N, Millan MJ (1998) Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. Naunyn-Schmiedebergs Arch Pharmacol 358:197–206
Nishikawa H, Inoue T, Izumi T, Koyama T (2007) Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats. Eur Neuropsychopharmacol 17:643–650
Nishitsuji K, To H, Murakami Y, Kodama K, Kobayashi D, Yamada T, Kubo C, Mine K (2004) Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression: results of a comparatively high dosage trial. Clin Drug Investig 24:121–126
Nishitsuji K, To H, Shimizu T, Yanase Y, Yamada T, Hara C, Mine K, Higuchi S (2006) The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress. Eur Neuropsychopharmacol 16:376–382
Ohno Y, Shimizu S, Imaki J (2009) Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice. J Pharmacol Sci 109:593–599
Ohno Y, Shimizu S, Imaki J, Ishihara S, Sofue N, Sasa M, Kawai Y (2008) Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test. Prog Neuropsychopharmacol Biol Psychiatry 32:1302–1307
Powell SB, Palomo J, Carasso BS, Bakshi VP, Geyer MA (2005) Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors. Psychopharmacology (Berl) 180:491–500
Sharp T, Foster GA (1991) Release of 5-hydroxytryptamine (5-HT) from medullary and mesencephalic raphe neurones after grafting to the rat hippocampus: evidence for regulation by 5-HT1A autoreceptors. Neurosci Lett 132:179–182
Sugimoto Y, Yamada J, Noma T (1998) Effects of anxiolytics, diazepam and tandospirone, on immobilization stress-induced hyperglycemia in mice. Life Sci 63:1221–1226
Sumiyoshi T, Bubenikova-Valesova V, Horacek J, Bert B (2008) Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 25:1037–1056
Sumiyoshi T, Higuchi Y, Matsui M, Arai H, Takamiya C, Meltzer HY, Kurachi M (2007a) Effective adjunctive use of tandospirone with perospirone for enhancing verbal memory and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31:965–967
Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C, Jayathilake K, Meltzer HY (2001a) Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722–1725
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY (2001b) The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry 49:861–868
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M, Meltzer HY (2000) Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20:386–388
Sumiyoshi T, Park S, Jayathilake K, Roy A, Ertugrul A, Meltzer HY (2007b) Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 95:158–168
Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL (2006) Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry 63:1325–1335
Tanaka H, Tatsuno T, Shimizu H, Hirose A, Kumasaka Y, Nakamura M (1995) Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Gen Pharmacol 26:1765–1772
Tatarczynska E, Pawlowski L, Chojnacka-Wojcik E, Maj J (1989) The central action of 1-(2-pyrimidinyl)-piperazine, an ipsapirone metabolite. Pol J Pharmacol Pharm 41:51–61
van den Buuse M (2010) Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 36:246–270
van den Buuse M, Gogos A (2007) Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition. J Pharmacol Exp Ther 320:1224–1236
Yeomans JS, Li L, Scott BW, Frankland PW (2002) Tactile, acoustic and vestibular systems sum to elicit the startle reflex. Neurosci Biobehav Rev 26:1–11
Yuen EY, Jiang Q, Chen P, Gu Z, Feng J, Yan Z (2005) Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. J Neurosci 25:5488–5501
Acknowledgements
The study was supported by project 1 M0517 from the Ministry of Education, Youth and Sports, and by project MZ0PCP2005 from the Grant Agency of the Ministry of Health, the Czech Republic.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bubenikova-Valesova, V., Svoboda, J., Horacek, J. et al. Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats. Psychopharmacology 212, 267–276 (2010). https://doi.org/10.1007/s00213-010-1951-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-010-1951-3